Centessa Files Definitive Proxy for Eli Lilly Acquisition Vote, Details $38.00 Cash + $9.00 CVR Deal

summarizeSummary

Centessa Pharmaceuticals plc has filed its definitive proxy statement, outlining the terms of its acquisition by Eli Lilly and Company for $38.00 cash per share plus a contingent value right (CVR) of up to $9.00 per share, and seeking shareholder approval for the transaction.

check_boxKey Events

• Definitive Acquisition Terms Confirmed

  The filing confirms the acquisition by Eli Lilly and Company for $38.00 cash per share, plus a non-transferable Contingent Value Right (CVR) potentially worth up to $9.00 per share, for a total potential value of $47.00 per share. The risk-adjusted value of the offer is $41.01 per share.

• Shareholder Vote Scheduled

  Shareholders will vote on the Scheme of Arrangement and a Company Shareholder Resolution at meetings on June 12, 2026, a critical step for the transaction's completion. The HSR waiting period is scheduled to expire on May 21, 2026.

• Board Recommends Approval

  The Company Board (excluding one director due to conflict) unanimously recommends shareholders vote "FOR" the acquisition proposals, citing the compelling price and certainty of value for shareholders.

• CVR Milestones Detailed

  The CVR payments are contingent on achieving specific regulatory approvals for ORX750 or ORX142 for various indications by set deadlines, with Eli Lilly committed to using commercially reasonable efforts to achieve these milestones.

auto_awesomeAnalysis

This definitive proxy statement is a crucial step in the previously announced acquisition of Centessa Pharmaceuticals by Eli Lilly and Company. It provides shareholders with the final details for their vote on the Scheme of Arrangement and related resolutions. The transaction offers a substantial premium over Centessa's pre-announcement trading price, providing immediate cash value and potential upside through the CVRs tied to regulatory milestones for key product candidates. The unanimous board recommendation and significant voting support from major shareholders indicate strong internal alignment for the deal. The CVR structure allows existing shareholders to participate in future success while mitigating the inherent risks of a clinical-stage biotechnology company. The current stock price is trading near its 52-week high, reflecting the market's positive outlook on the deal's completion and the potential value of the CVR.